| Title |
Enasidenib: First Global Approval
|
|---|---|
| Published in |
Drugs, September 2017
|
| DOI | 10.1007/s40265-017-0813-2 |
| Pubmed ID | |
| Authors |
Esther S. Kim |
| Abstract |
Enasidenib (Idhifa(®)) is an oral isocitrate dehydrogenase-2 (IDH2) inhibitor developed by Celgene Corporation under a global, exclusive license from Agios Pharmaceuticals. Enasidenib has been approved in the USA for the treatment of adults with relapsed or refractory acute myeloid leukaemia (AML) and an IDH2 mutation as detected by an FDA-approved test. It is at various stages of development in other countries for AML, myelodysplastic syndromes and solid tumours. This article summarizes the milestones in the development of enasidenib leading to this first global approval in the USA for the treatment of adults with relapsed or refractory IDH2-mutated AML. |
Mendeley readers
The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 87 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 22 | 25% |
| Researcher | 12 | 14% |
| Student > Master | 9 | 10% |
| Student > Bachelor | 8 | 9% |
| Student > Doctoral Student | 5 | 6% |
| Other | 12 | 14% |
| Unknown | 19 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 27 | 31% |
| Medicine and Dentistry | 12 | 14% |
| Chemistry | 8 | 9% |
| Agricultural and Biological Sciences | 5 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Other | 11 | 13% |
| Unknown | 19 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 July 2021.
All research outputs
#2,489,472
of 23,007,053 outputs
Outputs from Drugs
#278
of 3,287 outputs
Outputs of similar age
#49,439
of 315,595 outputs
Outputs of similar age from Drugs
#4
of 30 outputs
Altmetric has tracked 23,007,053 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,287 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,595 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.